Advocacy for Increased International Efforts for Antimicrobial Stewardship Actions in Low-and Middle-Income Countries on Behalf of Alliance for the Prudent Use of Antimicrobials (APUA), Under the Auspices of the International Society of Antimicrobial Chemotherapy (ISAC).
antibiotics
antimicrobial stewardship
education
low- and middle- income countries
resistance
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
01
2020
accepted:
21
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
epublish
Résumé
Antimicrobial stewardship (AMS) is a set of coordinated strategies to improve the use of antimicrobials, to enhance patient outcomes, reduce antimicrobial resistance, and decrease unnecessary costs. The pioneer years of AMS were restricted to high-income countries (HIC), where overconsumption of antibiotics was associated with emergence of multidrug-resistant (MDR) bacteria. AMS in low- and middle-income countries (LMIC) is also necessary. However, programs effective in HIC may not perform as well in LMIC, because (i) While decreased consumption of antibiotics may be an appropriate target in overconsuming HIC, this may be dangerous in LMIC, where many patients die from the lack of access to antibiotics; (ii) although AMS programs in HIC can be designed and monitored through laboratory surveillance of resistance, surveillance programs are not available in many LMIC; (iii) the heterogeneity of health care systems implies that AMS programs must be carefully contextualized. Despite the need to individually tailor AMS programs in LMIC, international collaborations remain highly valuable, through the dissemination of high-quality documents and educational material, that may be shared, adapted where needed, and adopted worldwide. This process, facilitated by modern communication tools, combines many benefits, including: (i) saving time, a precious dimension for health care workers, by avoiding the duplication of similar works in different settings; (ii) taking advantage of colleagues skills, and initiatives, through open access to the work performed in other parts of the world; (iii) sharing experiences, so that we all learn from each others' successes and failures.
Identifiants
pubmed: 32984380
doi: 10.3389/fmed.2020.00503
pmc: PMC7479847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
503Informations de copyright
Copyright © 2020 Tattevin, Levy Hara, Toumi, Enani, Coombs, Voss, Wertheim, Poda, Daoud, Laxminarayan, Nathwani and Gould.
Références
Lancet Infect Dis. 2017 Feb;17(2):e56-e63
pubmed: 27866945
J Antimicrob Chemother. 2018 Apr 1;73(4):1091-1097
pubmed: 29340600
Euro Surveill. 2015 May 28;20(21):
pubmed: 26062562
BMC Public Health. 2018 Apr 11;18(1):476
pubmed: 29642879
Pharmacoeconomics. 2018 Jul;36(7):731-732
pubmed: 29876877
J Antimicrob Chemother. 2016 May;71(5):1408-14
pubmed: 26869693
Lancet. 2016 Jan 9;387(10014):188-98
pubmed: 26603919
Bull World Health Organ. 2018 Apr 01;96(4):266-280
pubmed: 29695883
Front Microbiol. 2016 Sep 13;7:1406
pubmed: 27679613
Int J Infect Dis. 2019 Sep;86:25-30
pubmed: 31189085
Clin Microbiol Infect. 2017 Nov;23(11):812-818
pubmed: 28712667
Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S97-100
pubmed: 25261548
J Antimicrob Chemother. 2018 May 1;73(5):1408-1415
pubmed: 29462430
J Antimicrob Chemother. 2011 Jun;66 Suppl 5:v3-12
pubmed: 21680584
Intensive Care Med. 2018 Jan;44(1):79-82
pubmed: 28409205
PLoS One. 2019 Jan 16;14(1):e0209847
pubmed: 30650099
BMJ. 1998 Sep 5;317(7159):668-71
pubmed: 9728003
J Antimicrob Chemother. 2017 Nov 1;72(11):3199-3204
pubmed: 28961862
Clin Infect Dis. 2012 Jun;54(11):1581-7
pubmed: 22495073
Cardiovasc J Afr. 2017 Jul/Aug;28(4):242-247
pubmed: 28906539
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
Clin Infect Dis. 2007 Jan 15;44(2):159-77
pubmed: 17173212
Science. 2016 Aug 26;353(6302):874-5
pubmed: 27540009
BMJ Open Qual. 2018 Dec 16;7(4):e000495
pubmed: 30623113
PLoS One. 2018 Dec 20;13(12):e0208447
pubmed: 30571688
Microb Drug Resist. 2017 Jan;23(1):63-70
pubmed: 27092971
PLoS One. 2019 Aug 5;14(8):e0220261
pubmed: 31381579
Front Microbiol. 2011 Nov 24;2:230
pubmed: 22164154
PLoS Med. 2019 Mar 29;16(3):e1002774
pubmed: 30925166
Clin Microbiol Infect. 2019 Jan;25(1):20-25
pubmed: 29625170
Int J Antimicrob Agents. 2016 Sep;48(3):239-46
pubmed: 27502752
Infect Control Hosp Epidemiol. 2019 May;40(5):512-519
pubmed: 31084674
S Afr Med J. 2016 Sep 06;106(10):947-948
pubmed: 27725009
Lancet. 2016 Jan 9;387(10014):168-75
pubmed: 26603918
Health Policy Plan. 2017 May 1;32(4):487-492
pubmed: 28025321
New Horiz. 1996 Aug;4(3):370-6
pubmed: 8856755
Lancet. 2018 May 12;391(10133):1873-1875
pubmed: 29550031
Clin Microbiol Infect. 2017 Apr;23(4):216-218
pubmed: 28274769
Br J Clin Pharmacol. 2012 Jul;74(1):171-9
pubmed: 22150975
PLoS Med. 2018 Mar 1;15(3):e1002521
pubmed: 29494582